Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-11-15
2005-11-15
Huff, Sheela J. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387700, C530S388100, C530S388800, C530S388850, C530S389100, C530S389700
Reexamination Certificate
active
06965017
ABSTRACT:
The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
REFERENCES:
patent: 5262177 (1993-11-01), Brown et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5620886 (1997-04-01), Brichard et al.
patent: 3341367 (1984-05-01), None
patent: 0668350 (1995-08-01), None
patent: 213543 (1984-08-01), None
patent: WO 92/21767 (1992-10-01), None
patent: 9314189 (1993-07-01), None
patent: 94/21126 (1994-09-01), None
patent: 9423067 (1994-10-01), None
patent: 9522561 (1995-08-01), None
Campbell, Monoclonal Antibody Technology, Eds. Elsevier Science Publishers Chapter 1, pp. 1-32 (1986).
Coulie, P.G. et al. (1993) “Genes coding for tumor antigens recognized by human cytolytic T-lymphocytes”J. Immunotherap, 14:104-109.
Coulie P.G. et al. “A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas”,J. Exp Med(1994) 180:35-42.
Mareah, C.A. et al.: Cloning and expression of the gene for the melanoma associated ME20 antigen.DNA and Cell Biology, 1994; 13:87-95.
Cox, A.L., et al. “Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines”Science1994; 264:716-719.
Brichard, V., et al.: “The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas”,J. Exp. Med. 1993; 178:489-495.
Gaugler, B., et al. “Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes”.J. Esp. Med. 1994; 179:921-930.
Traversari, C., et al.: “A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E”.J. Exp. Med. 1992; 176:1453-1457.
Cellis, E., et al.: “Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptides epitopes”.Proc. Natl. Acad. Sci. U.S.A.1994; 91:2105-2109.
Boon, T.: “Toward a genetic analysis of tumor rejection antigens”.Adv. Cancer Res. 1992; 58:177-210.
Kawakami, Y., et al.; T-cell recognition of human melanoma antigens,J. Immunother. 1993; 14:88-93.
Bakker, A.B.H., et al.: Melanocyte lineage-specific antigen gp 100 is recognized by melanocyte-derived tumor infiltrating lymphocytes.J. Exp. Med. 1994; 179:1005-1009.
Wōlfel, T., et al.: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T. lymphocytes.Eur. J. Immunol. 1994; 24:759-764.
Adams, G.J., et al.: Melanocyte lineage-specific anigens recognized by monoclonal antibodies NKI-beteb, HMB-50. and HMB-45 are encoded by a single cDNA.Am J. Pathol. 1993; 143:1579-1585.
Kwon, B.S., et al.: A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosom 10 and is in a syntenic region on human chromosome 12.Proc. Natl. Acad. Sci. USA1991; 88:9228-9232.
Rosenberg, S.A., et al.: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report.N. Engl. J. Med. 1988; 319:1676-1680.
Kawakami, Y., et al.,: Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2. transfected melanomas.J Immunol1992; 148:638-643.
Van der Bruggen, et al.: A gene encoding an antigen recognized by cytolytic T. lymphocytes on a human melanoma.Science1991; 254:1643-1647.
Falk, K., et al.: “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.”Nature1991, 351:290-296.
Kubo, R., et al.: “Definition of specific peptide motifs for four major HLA-A Alleles.”Journal of Immunology1994, 152:3913-3924.
Parker, K., et al.: “Sequence motifs important for peptide binding to the human MHC class 1 molecule. HLA-A2,” 1992, J. Immunol:3580-3587.
Ruppert, J., et al.: “Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules.”Cell1993, 74:929-937.
Storkus, W., et al.: “Identification of human melanoma peptides recognized by class 1 restricted tumor infilturating T lymphocytes.”Journal of Immunology1993, 151:3719-3727.
Kawakami, Y., et al.: “Cloning of the gene coding for a shard human melanoma antigen recognized by autologous T cells infiltrating into tumor.”Pro. Natl. Acad. Sci. USA1994, 91:3515-3519.
Adams, G.J. et al., “Molecular characterization of the melanocyte lineage-specific antigen gp 100.”Journal of Biological Chemistry1994, 269:20126-20133.
EMBL Database Accession No. M32295:Nov. 26, 1990 Vogel A.: Human KD melanocyte specific secreted glycoprotein MRNA 3‘end’.
Kawakami, Y., et al., “Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection”PNAS91:6458-6462 1994.
Kawakami, Y., et al., “Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes”J. Exp. Med. 180:347-352, 1994.
Rivoltini, L., et al., “Induction of Tumor-Reactive CTL from Peripheral Blood and Tumor-Infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART 1”Journal of Immunology, 1995, 154:2257-2265.
Slingluff, C.L.,Jr., et al., “Direct analysis of tumor-associated peptide antigens”Current Opinion in Immunology1994 6:733-740.
Cole, D.J., et al., “Characterization of the Functional Specificity of a Cloned T-Cell Receptor Heterodimer Recognizin the MART-1 Melanoma Antigen”Cancer Res. 55:748-752 Feb. 1995.
Cole, D.J., et al., “Identification of MART-1-specific T Cell Receptors: T-Cells Utilizing Distinct T-Cell Receptor Variable and Joining Regions Recognize the Same Tumor Epitope”Cancer Res. 54:5265-5268, 1994.
Castelli, C., et al., “Mass Spectrometric Identification of a Naturally Processed Melanoma Peptide Recognized by CD8+Cytotoxic T Lymphocytes”J. Exp. Med. 181:363-368 1995.
Sette, A., et al., “Peptide Binding To The Most Frequent HLA-A Class I Alleles Measured By Quantitative Molecular Binding Assays”Molecular Immunology31:813-822, 1994.
Wōlfel, T., et al., “Analysis Of Antigens Recognized On Human Melanoma Cells By A2-Restricted Cytolytic T Lymphocytes (CTL)”Int. J. Cancer55:237-244, 1993.
Wōlfel, T., et al., “Isolation Of Naturally Processed Peptides Recognized by Cytolytic Lymphocytes (CTL) On Human Melanoma Cells In Association With HLA-A2.1”Int. J. Cancer57:413-418, 1994.
Topalian, S.L., et al., “Human CD4+T Cells Specifically Recognize a Shared Melanoma-Associated Antigen Encoded by the Tyrosinase Gene”PNAS91:9461-9465, 1994.
Boēl, P., et al., “BAGE: a New Gene Encoding an Antigen Recognized on Human Melanomas Cytolytic T Lymphocytes”Immunity2:167-175 1995.
Slingluff, C.L., Jr., et al., “Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocyte Is Mediated by at Least Six Shared Peptide Epitopes”Journal of Immunology150:2955-2963 1993.
GenBank Database Accession No. M77348—Human PMEL 17 in RNA—Jan. 8, 1995.
GenBank Database Accession No. U06654—Human Differentiation Antigen Melan-A Protein in RNA—J
Kawakami Yutaka
Rosenberg Steven A.
Huff Sheela J.
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
LandOfFree
Melanoma antigens and their use in diagnostic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Melanoma antigens and their use in diagnostic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanoma antigens and their use in diagnostic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3483604